Formosa Pharmaceuticals and the Singapore Eye Research Institute (SERI) have entered a research collaboration to develop ophthalmic formulations for corneal and ocular surface diseases.

• Core Technology: Utilises Formosa’s Active Pharmaceutical Nanoparticle Technology (APNT) to improve drug delivery of active pharmaceutical ingredients.
• Research Scope: Focuses on developing formulations for corneal and ocular surface conditions.
• Clinical Objective: Aims to enhance the efficacy, bioavailability, and safety of topical ocular therapies.

This summary is based on a news article published by BioSpectrum Asia.

Image for illustrative purposes only. Source: Canva.